FORMA Therapeutics

FORMA Therapeutics

Improving the lives of people with diabetes and other chronic conditions. Learn more

Launch date
Employees
Market cap
$958m
Enterprise valuation
$594m (Public information from Nov 2022)
Watertown Massachusetts (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR20192020202120222023
Revenues--6.4m-6.4m
EBITDA-(112m)(159m)(190m)(217m)
% EBITDA margin--(2500 %)-(3414 %)
Profit-(67.3m)(151m)(178m)(207m)
% profit margin--(2371 %)-(3257 %)
EV / revenue--0.7x--
EV / EBITDA--8.7x-0.0x-0.8x-
R&D budget99.0m----

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-

$4.0m

Series A

$25.5m

Series B

$3.0m

Series B

$10.0m

Early VC

$100m

Series D
N/A

N/A

IPO
*

$1.1b

Valuation: $1.1b

157.1x EV/LTM Revenues

-6.3x EV/LTM EBITDA

Acquisition
Total Funding$143m

Recent News about FORMA Therapeutics

Edit
More about FORMA Therapeuticsinfo icon
Edit

Forma Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing transformative medicines for patients with rare hematologic diseases and cancers. The company operates in the biopharmaceutical sector, focusing on innovative drug discovery and development. Forma Therapeutics serves patients, healthcare providers, and the broader medical community by addressing unmet medical needs with novel therapeutic solutions. The business model revolves around research and development, clinical trials, and eventual commercialization of its drug candidates. Revenue is primarily generated through partnerships, licensing agreements, and future product sales. Forma Therapeutics emphasizes patient-centric approaches, integrating patient and community insights into their scientific endeavors to ensure impactful outcomes.

Keywords: biopharmaceutical, clinical-stage, transformative medicines, rare diseases, hematologic, cancers, drug discovery, patient-centric, innovation, therapeutic solutions.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.